Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype

Sponsor
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Study ID
NCT05574673
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Standard of care — OTHER
    Patients receive standard of care treatment according to local and national guidelines

Study Details

This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.

Key Dates

First listed
Oct 10, 2022
Start date
Dec 1, 2022
Status verified
Feb 2026
Primary completion
May 1, 2028
Completion
Jul 1, 2032

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Ovarian cancer patients
    Newly diagnosed patients with ovarian cancer, fallopian tube cancer or primary peritoneal cancer

Primary Outcome Measure

Endpoint OP1 [ Time Frame: 60 months ]

Central Contacts

Find similar trials

Nationwide
Ovarian cancer trialsOncology trialsGynecologic oncology trialsWomen's health trials

Related Studies